|
Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy inadvanced nonsquamous non–small cell lung cancer (WJOG 5910L): An open-label, randomized, phase II trial. |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - AstraZeneca; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Fuji Pharma; Hisamitsu Pharmaceutical; Kyowa Hakko Kirin; Lilly; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly |
Speakers' Bureau - AstraZeneca; Lilly; Merck Serono |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - AstraZeneca (Inst); Lilly (Inst); MSD (Inst); Ono Pharmaceutical (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; Clovis Oncology |
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo; Nippon Boehringer Ingelheim; Nippon Kayaku; Pfizer; Taiho Pharmaceutical |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Clovis Oncology (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Novartis (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst) |
|
|
No Relationships to Disclose |
|
|
Honoraria - Chugai Pharma |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Lilly; Nippon Boehringer Ingelheim; Pfizer; Taiho Pharmaceutical |
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst) |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; MSD; Taiho Pharmaceutical; Takeda |
|
|
Honoraria - Chugai Pharma |
Research Funding - Chugai Pharma (Inst) |
|
|
Honoraria - Chugai Pharma |
Speakers' Bureau - Chugai Pharma |
Research Funding - Chugai Pharma (Inst) |
|
|
Honoraria - Chugai Pharma |